What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has received 10 analyst ratings in the last quarter, with 3 being bullish and 7 somewhat bullish. The company's average price target has increased by 3.61% from the previous average price target of $75.57 to $78.3.
August 22, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies has received positive analyst ratings, which could potentially boost investor confidence and positively impact the stock price.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings and increased price target for Intra-Cellular Therapies indicate a positive outlook for the company, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100